1511 GMT - Novo Nordisk first-quarter earnings could miss expectations on lower-than-expected prescriptions of Ozempic and Wegovy as well as some price declines, Bank of America Securities analysts write. Growth will also be hit by tough comparables, currency impacts and possibly higher costs, the bank says. "We expect sales guide to be lowered from 16-24% at constant exchange rates to 14%-22%, with our forecasts at the bottom of the new range." BofA assumes limited Ozempic/Wegovy inflection in the second quarter, while a key unknown is if whether a second-half inflection in prescriptions happens against tougher comparables. The bank lowers its price objective to 910 Danish kroner from 1,075 kroner and keeps a buy rating. Shares trade at 475.00 kroner. (dominic.chopping@wsj.com)
(END) Dow Jones Newswires
March 28, 2025 11:11 ET (15:11 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。